Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O STERN

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Antimicrobial Agents and Chemotherapy|November 13, 2013
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevirKristi L Berger, Ibtissem Triki, Mireille Cartier, et al.
Plos One|August 6, 2016
Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and FaldaprevirKristi L Berger, Christoph Sarrazin, David R Nelson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 30, 2014
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b studyStefan Zeuzem, Jean-François Dufour, Maria Buti, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 2014
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patientsRucha S Sane, Gerhard G Steinmann, Qihong Huang, et al.
Antimicrobial Agents and Chemotherapy|April 9, 2014
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patientsDouglas Dieterich, Tarik Asselah, Dominique Guyader, et al.
Antimicrobial Agents and Chemotherapy|July 17, 2013
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis CDominique Larrey, Ansgar W Lohse, Christian Trepo, et al.
European Journal of Gastroenterology & Hepatology|May 4, 2016
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b studyStefan Zeuzem, Parvez Mantry, Vicente Soriano, et al.
AIDS (London, England)|February 25, 2015
Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIVDouglas Dieterich, Mark Nelson, Vicente Soriano, et al.
Hepatology (Baltimore, Md.)|January 30, 2013
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trialMark S Sulkowski, Tarik Asselah, Jacob Lalezari, et al.
Journal of Hepatology|December 15, 2010
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infectionMichael P Manns, Marc Bourlière, Yves Benhamou, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Antimicrobial Agents and Chemotherapy|November 13, 2013
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevirKristi L Berger, Ibtissem Triki, Mireille Cartier, et al.
Plos One|August 6, 2016
Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and FaldaprevirKristi L Berger, Christoph Sarrazin, David R Nelson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 30, 2014
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b studyStefan Zeuzem, Jean-François Dufour, Maria Buti, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 2014
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patientsRucha S Sane, Gerhard G Steinmann, Qihong Huang, et al.
Antimicrobial Agents and Chemotherapy|April 9, 2014
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patientsDouglas Dieterich, Tarik Asselah, Dominique Guyader, et al.
Antimicrobial Agents and Chemotherapy|July 17, 2013
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis CDominique Larrey, Ansgar W Lohse, Christian Trepo, et al.
European Journal of Gastroenterology & Hepatology|May 4, 2016
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b studyStefan Zeuzem, Parvez Mantry, Vicente Soriano, et al.
AIDS (London, England)|February 25, 2015
Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIVDouglas Dieterich, Mark Nelson, Vicente Soriano, et al.
Hepatology (Baltimore, Md.)|January 30, 2013
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trialMark S Sulkowski, Tarik Asselah, Jacob Lalezari, et al.
Journal of Hepatology|December 15, 2010
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infectionMichael P Manns, Marc Bourlière, Yves Benhamou, et al.
Pageof 8